Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine secreted by epithelial cells that acts as an alarmin in response to environmental insults.
Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors.
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. The company’s portfolio includes GIP antibody conjugates designed to address specific obesity subpopulations.
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI).
Malaria remains a significant global health challenge, causing over 600,000 deaths annually despite existing prevention and treatment measures. Current vaccines and monoclonal antibodies (mAbs) against Plasmodium falciparum, such as RTS,S/AS01 and R21, primarily target the central repeat region of the circumsporozoite protein (CSP) but have shown limited efficacy in completely preventing infection.
Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy, in the territory outside of Greater China.
Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 (177Lu-RAD-202) for the treatment of HER2-expressing solid tumors, including breast and gastric cancers.
Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
RSS
